These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 34115611)

  • 21. Efficacy and safety of roxadustat for anaemia in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: A systematic review and meta-analysis.
    Zheng L; Tian J; Liu D; Zhao Y; Fang X; Zhang Y; Liu Y
    Br J Clin Pharmacol; 2022 Mar; 88(3):919-932. PubMed ID: 34428860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy and safety of roxadustat treatment for anemia in patients with kidney disease: a meta-analysis and systematic review.
    Qie S; Jiao N; Duan K; Li J; Liu Y; Liu G
    Int Urol Nephrol; 2021 May; 53(5):985-997. PubMed ID: 33389461
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase 3b, multicenter, open-label, single-arm study of roxadustat within a US dialysis organization: The DENALI study.
    Larkin J; Hymes J; Britton ML; Oluwatosin Y; Nolen J; Zhu L; Silva A
    Hemodial Int; 2024 Jan; 28(1):59-71. PubMed ID: 37875459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short-term effect of low-dose roxadustat combined with erythropoiesis-stimulating agent treatment for erythropoietin-resistant anemia in patients undergoing maintenance hemodialysis.
    Xu Q; Huang J; Liu Q; Wang X; Liu H; Song Y; Dou F; Lv S; Liu G
    Front Endocrinol (Lausanne); 2024; 15():1372150. PubMed ID: 39010898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES).
    Barratt J; Andric B; Tataradze A; Schömig M; Reusch M; Valluri U; Mariat C
    Nephrol Dial Transplant; 2021 Aug; 36(9):1616-1628. PubMed ID: 34077510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase 3b, multicenter, open-label, single-arm study of roxadustat (ASPEN): Operational learnings within United States dialysis organizations.
    Fishbane S; Vishnepolsky M; Oluwatosin Y; Nolen J; Zhu L; Cooper K; Young A
    Hemodial Int; 2023 Oct; 27(4):400-410. PubMed ID: 37380364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS).
    Shutov E; Sułowicz W; Esposito C; Tataradze A; Andric B; Reusch M; Valluri U; Dimkovic N
    Nephrol Dial Transplant; 2021 Aug; 36(9):1629-1639. PubMed ID: 33630072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis.
    Tian L; Wang M; Liu M; Pang Y; Zhao J; Zheng B; Wang Y; Zhao W
    Ren Fail; 2024 Dec; 46(1):2313864. PubMed ID: 38345037
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Roxadustat treatment for anemia in peritoneal dialysis patients: A randomized controlled trial.
    Hou YP; Mao XY; Wang C; Xu ZH; Bu ZH; Xu M; Li B
    J Formos Med Assoc; 2022 Feb; 121(2):529-538. PubMed ID: 34167878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in Iron Availability with Roxadustat in Nondialysis- and Dialysis-Dependent Patients with Anemia of CKD.
    Pergola PE; Charytan C; Little DJ; Tham S; Szczech L; Leong R; Fishbane S
    Kidney360; 2022 Sep; 3(9):1511-1528. PubMed ID: 36245647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Roxadustat in the treatment of anaemia in chronic kidney disease.
    Del Vecchio L; Locatelli F
    Expert Opin Investig Drugs; 2018 Jan; 27(1):125-133. PubMed ID: 29254377
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A New Approach to the Management of Anemia in CKD Patients: A Review on Roxadustat.
    Becker K; Saad M
    Adv Ther; 2017 Apr; 34(4):848-853. PubMed ID: 28290095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A retrospective study on the efficacy of Roxadustat in peritoneal dialysis patients with erythropoietin hyporesponsiveness.
    Liu J; Li S; Yang F; Li T; Li R; Waheed Y; Meng C; Li S; Liu K; Tong Y; Xu H; Tian C; Zhou X
    Korean J Intern Med; 2024 May; 39(3):488-500. PubMed ID: 38649158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical effect of roxadustat vs. erythropoietin in non-dialysis CKD with diabetes: a single center propensity score matching analysis.
    Jin C; Ren Y; Wang M; Hu X; Shang Y; Li Y; Zhu B; He Q; Shao L
    Int Urol Nephrol; 2024 Aug; 56(8):2683-2693. PubMed ID: 38489143
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical efficacy of combined ESA and Roxadustat treatment for renal anemia in hemodialysis patients with secondary hyperparathyroidism: A case series.
    Zhong JJ; Wang ML; Zheng GF; Li MP; Chen DZ
    Medicine (Baltimore); 2024 Aug; 103(33):e39083. PubMed ID: 39151521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Red blood cell lifespan in long-term hemodialysis patients treated with roxadustat or recombinant human erythropoietin.
    Yang X; Zhao B; Wang J; Wang L; Tao M; Lu J; Lin J; Sun J; Wang R
    Ren Fail; 2021 Dec; 43(1):1428-1436. PubMed ID: 34657570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients.
    Song J; Chen X; Zhou L; Yu W; Liu H; Yuan F
    J Int Med Res; 2023 Oct; 51(10):3000605231204475. PubMed ID: 37843847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.
    Provenzano R; Besarab A; Sun CH; Diamond SA; Durham JH; Cangiano JL; Aiello JR; Novak JE; Lee T; Leong R; Roberts BK; Saikali KG; Hemmerich S; Szczech LA; Yu KP; Neff TB
    Clin J Am Soc Nephrol; 2016 Jun; 11(6):982-991. PubMed ID: 27094610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.
    Chen N; Qian J; Chen J; Yu X; Mei C; Hao C; Jiang G; Lin H; Zhang X; Zuo L; He Q; Fu P; Li X; Ni D; Hemmerich S; Liu C; Szczech L; Besarab A; Neff TB; Peony Yu KH; Valone FH
    Nephrol Dial Transplant; 2017 Aug; 32(8):1373-1386. PubMed ID: 28371815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy and safety of roxadustat for the treatment of anemia in non-dialysis dependent chronic kidney disease patients: An updated systematic review and meta-analysis of randomized clinical trials.
    Abdelazeem B; Shehata J; Abbas KS; El-Shahat NA; Malik B; Savarapu P; Eltobgy M; Kunadi A
    PLoS One; 2022; 17(4):e0266243. PubMed ID: 35363823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.